Intravenous tranexamic acid reduces blood loss and transfusion requirements after periacetabular osteotomy: a placebo-controlled, double-blind randomized clinical trial. (14th September 2020)

• Record Type: Journal Article
• Authors: Levack, Ashley E.; McLawhorn, Alexander S.; Dodwell, Emily; DelPizzo, Kathryn; Nguyen, Joseph; Sink, Ernest
• Is Part Of: Bone & joint journal. Volume 102B:Number 9(2020)
• Page Start: 1151
• Page End: 1157
• Publication Date: 2020-09-14
• Subjects: Tranexamic acid -- Periacetabular osteotomy -- Calculated blood loss -- Transfusion -- Acetabular dysplasia -- Antifibrinolytics; Bones -- Surgery -- Periodicals; Joints -- Surgery -- Periodicals; Orthopedic surgery -- Periodicals; 617.47005
• DOI: 10.1302/0301-620X.102B9.BJJ-2019-1777.R1
• Languages: English
• ISSNs: 2049-4394

Abstract

Abstract : Aims: Tranexamic acid (TXA) has been shown to reduce blood loss and transfusion requirements in patients undergoing orthopaedic surgery. There remains a lack of prospective evidence for the use of TXA in patients undergoing periacetabular osteotomy (PAO). The purpose of this study was to determine if intravenous (IV) TXA is effective in reducing calculated blood loss and transfusions after PAO. Methods: This was a single-centre prospective double-blind placebo-controlled randomized trial of 81 patients aged 12 to 45 years undergoing elective PAO by a single surgeon. The intervention group (n = 40) received two doses of IV TXA of a maximum 1 g in each dose; the control group (n = 41) received two doses of 50 ml 0.9% saline IV. The primary outcome was perioperative calculated blood loss. Secondary outcomes included allogenic transfusions and six-week postoperative complications. Results: There were no differences in demographics or intraoperative variables between study groups. The TXA group demonstrated lower mean calculated blood loss (1, 265 ml, (SD 321) vs 1, 515 ml, (SD 394); p = 0.002) and lower frequency of allogenic transfusion (10%/n = 4 vs 37%/n = 15; p = 0.008). Regression analyses associated TXA use with significant reductions in calculated blood loss (p < 0.001) and transfusion (p = 0.007) after adjusting for age, sex, body mass index, preoperative haemoglobin, cell-saver volume, intraoperative mean arterial blood pressure, and operating time. No patients suffered venous thromboembolic complications. Conclusion: In this trial, IV TXA decreased postoperative calculated blood loss by 293 ml and reduced the frequency of allogenic transfusions by 73% (37% vs 10%) following PAO. TXA may be safe and effective for reducing blood loss in patients undergoing PAO. Cite this article: Bone Joint J 2020;102-B(9):1151–1157.